eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
vol. 12

Recurrence of testicular cancer – only VeIP?

Grzegorz Świątoniowski
Szymon Brużewicz

Współczesna Onkologia (2008) vol. 12; 1 (20–24)
Online publish date: 2008/03/20
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
The recurrence of germ cell tumours (GCT) after radical treatment still gives the possibility of successful treatment. There are some objective difficulties in the optimization of therapy, however, which are mostly related to the deficiency of highly reliable clinical data. Studies carried out in the 1980s revealed that ifosfamide- or cisplatin-based therapeutic protocols are efficient in the cases discussed. Their application may result in slightly more than 20% of recoveries. Many hopes are place on attempts with so-called “new drugs” – particularly paclitaxel and gemcitabine – used together with cisplatin in second line treatment. There are some reports which suggest the predominance of such programmes over the classical ifosfamide- and cisplatin-based therapies. An alternative approach is the application of high-dose chemotherapy (HDCT) with subsequent bone marrow or – currently more frequent – stem cell transplantation. Markedly over-treated patients (second recurrence) were qualified to early phase I/II trials, however, which was reflected in their results (low efficiency and poor tolerance of HDCT). The results became more promising when more restricted qualification criteria were used (only patients with first recurrence, exclusion of subjects with primary mediastinal location) and the transplantation techniques improved. Unfortunately, a phase III trial (IT 94) did not prove the advantages of HDCT over non-myeloablative treatment of recurrent GCT. There is some new evidence, however, according to which HDCT is advisable in certain groups of patients.

germ-cell tumour, recurrence, prognostic factors, chemotherapy, high-dose chemotherapy

Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe